Pre-clinical Trials of the Russian Vaccines Specific Activity Will Be Held before June 22

03 April 2020

GMP News

Russia will complete pre-clinical trials of the vaccines against the novel coronavirus (COVID-19) developed at the Vector State Research Center of Virology and Biotechnology in Novosibirsk before June 22, Russian Deputy Prime Minister Tatyana Golikova said during a video call between Russian President Vladimir Putin and the Russian government.

“Pre-clinical trials of the vaccine’s specific activity will be held before June 22. After that, the first phase of clinical trials to estimate safety and immunogenicity of the vaccine will begin on a restricted number of people, about 60 volunteers. We plan to begin such first stage trials on June 29 of this year,” she said.

Tatyana Golikova added that 22 new drugs developed at the Siberian Branch of the Russian Academy of Sciences are also being tested, with the results set to be made available on April 10.

“Currently, we are researching eight drugs already registered in the Russian Federation. We will have verifiable data on their effectiveness against the novel coronavirus infection on April 10,” Golikova said.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more